Search
Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010.
Immunisation is the most effective way of protecting your child against a range of serious illnesses, including measles, hepatitis B and whooping cough. All vaccines used in Australia undergo stringent testing and ongoing monitoring.
News headlines about the large number of life-threatening cases of the flu in Western Australia this winter have been hard to miss - find out what you can do to protect your family.
A new research project aims to demonstrate how influenza vaccination in children could be a highly cost-effective health care intervention in Australia.
Children with chronic medical diseases are at an unacceptable risk of hospitalisation and death from influenza and SARS-CoV-2 infections. Over the past two decades, behavioural scientists have learnt how to design non-coercive 'nudge' interventions to encourage positive health behaviours. Our study aims to evaluate the impact of multicomponent nudge interventions on the uptake of COVID-19 and influenza vaccines in medically at-risk children.
It's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.
Babies worldwide could have access to life-saving influenza vaccinations from just eight weeks of age thanks to researchers at The Kids Research Institute Australia and the generous support of the Telethon community.
More young Western Australians will have access to needle-free protection against influenza this winter, with the WA Government expanding its nation-leading FluMist® program to include teenagers aged 12 to 17 years.
Nontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.
The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.